Bandaram Pharma Packtech Limited has submitted its notice for the 1st Extraordinary General Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, scheduled for April 27, 2026.

EGM Submission and Compliance

The company formally submitted the EGM notice to BSE Limited on April 3, 2026, signed by Chairman and Managing Director Deepak Bandaram (DIN: 07074102). The meeting will be conducted through Video Conference/Other Audio-Visual Means (VC/OAVM) facility at 11:00 a.m.

Key Agenda Items

The EGM will address three significant resolutions requiring shareholder approval:

Director Appointment

Appointment of Mr. Eswar Reddy Putturu (DIN: 11510880) as Independent Director for a five-year term from January 30, 2026, to January 29, 2031. The MBA professional with expertise in finance and marketing holds 24,371 equity shares (0.20%) in the company.

Material Related Party Transactions

Two separate proposals for material RPTs with subsidiary VSR Paper and Packaging Limited:

Financial Context and Rationale

The proposed transactions represent 135.26% of Bandaram Pharma Packtech's annual consolidated turnover of ₹36.96 crores. The company holds 51.08% equity stake in VSR Paper and Packaging Limited, which reported turnover of ₹35.37 crores and profit after tax of ₹0.85 crores.

Corporate Governance Framework

The transactions require shareholder approval as they exceed the 10% materiality threshold of ₹3.696 crores based on annual consolidated turnover. The Audit Committee and Board have approved these transactions, emphasizing the strategic importance of VSR Paper as a key vendor for raw materials and finished goods distribution.

The company has appointed Vivek Surana & Associates as scrutinizer for the e-voting process, with remote e-voting available from April 24-26, 2026. Related parties will abstain from voting on the resolutions as per regulatory requirements.

Bandaram Pharma Packtech Limited has announced its unaudited financial results for the quarter and nine months ended 31.12.2025. The Board of Directors approved the standalone and consolidated financial results along with limited review reports during their meeting held on 13.02.2026 at 4:30 p.m. at the company's registered office in Bangalore, concluding at 7:10 p.m.

Regulatory Compliance and Board Meeting

The company submitted its outcome under Regulation 30 read with 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to BSE Limited. The results were prepared in accordance with Ind AS-34 "Interim Financial Reporting" and reviewed by statutory auditors M M Reddy & Co., Chartered Accountants, who provided limited review reports for both standalone and consolidated results.

Financial Performance Overview

The company's financial performance for Q3FY26 showed contrasting results between standalone and consolidated operations. The results demonstrate the impact of the company's subsidiary operations on overall performance.

Nine Months Performance Analysis

For the nine months ended 31.12.2025, the company's performance showed different trends across standalone and consolidated operations.

Earnings Per Share Details

The company reported earnings per share figures for both basic and diluted calculations across continuing operations.

Subsidiary Operations

The consolidated results include the performance of two subsidiary companies. VSR Paper & Packaging Limited, in which Bandaram Pharma Packtech holds a 55% stake, and Craftsmart Products Private Limited, which is 100% owned by the company. According to the auditor's review report, VSR Paper and Packaging Limited reported total revenues of Rs. 1,398.76 lakhs and net profit of Rs. 73.76 lakhs for Q3FY26, while Craftsmart Products Private Limited recorded revenues of Rs. 25.38 lakhs and net profit of Rs. 0.38 lakhs.

Corporate Actions and Compliance

The company has acquired shareholders of Craftsmart Products Private Limited on a swap basis in the ratio of 5:4, meaning for every 5 equity shares of Rs. 10 each held in Craftsmart Products Private Limited, 4 equity shares of Rs. 10 each of Bandaram Pharma Packtech Limited will be issued. The financial results have been prepared in accordance with Ind AS-34 "Interim Financial Reporting" and have been reviewed by statutory auditors M M Reddy & Co., Chartered Accountants, who provided limited review reports for both standalone and consolidated results.